BIG 16-05/AFT-27 (IMpassion030): A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti-PD-L1) Antibody in Combination with Adjuvant Anthracycline/Taxane-Based Chemotherapy versus Chemotherapy Alone in Patients with Operable Trip-Negative Breast Cancer

A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti-PD-L1) Antibody in Combination with Adjuvant Anthracycline/Taxane-Based Chemotherapy versus Chemotherapy Alone in Patients with Operable Trip-Negative Breast Cancer https://clinicaltrials.gov/ct2/show/NCT03498716
BIG 16-05/AFT-27
Cancer
Peter Bushunow, MD
Enrolling
Blair Thomas, RN BSN
(585) 747-4555